reports
Important Information for Zynerba Pharmaceuticals Stockholders to Tend...
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc. (“Harmony”) and its wholly owned subsidiary, Xylophone Acquisition Corp. (“Purchaser”), to purc...
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before ...
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We urge you to promptly tender your shares in response to the pending tender...
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeti...
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT DEVON, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) is August 25, 2023 at 9:00 a.m. EDT in order to provide stockholders additional time to consider and vote on Proposal...
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeti...
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting Annual Meeting to Reconvene on August 11, 2023 at 9:00 a.m. EDT DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) is August 11, 2023 at 9:00 a.m. EDT in order to provide stockholders additional time to consider and vote on Proposal...
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meetin...
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) was reconvened and then adjourned, without conducting any business, in order t...
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual N...
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference being held June 26, 2023. Investors interested in arranging a virtual meeting with the Company’s management during the conference ...
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meetin...
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting Meeting adjourned with respect to Proposal 2, Reverse Stock Split; Company encourages additional stockholders of record to vote before reconvened meeting on June 28, 2023 All other proposals approved DEVON, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that it has adjourned its 2023 Annual Meeting of Stockholders (“Annua...
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at t...
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced an oral podium presentation and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023), being held May 30 – June 2, 2023, in Miami, Fla. Copies of the presentations will be made available on the Zynerba ...
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results a...
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash equivalents at March 31, 2023; Cash runway to mid-year 2024 Proposal for a reverse stock split is on the agenda for June 13, 2023 annual meeting of stockholders to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market DEVON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- , ...
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg...
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q DEVON, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the le...
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gat...
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of two posters at the 55th Gatlinburg Conference, being held April 10-13, 2023, in Kansas City, Mo. Copies of the posters will be made available on the Zynerba corporate website following the presentation at . Wednesday Poster Presentation Details Title: Long-term Safety and Su...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Fina...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug designation for cannabidiol, the active ingredient in Zygel, in 22q11.2 deletion syndrome $50.6 million in cash and cash equivalents at December 31, 2022; Cash runway to mid-year 2024 DEVON, Pa., March 28, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative ph...
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securiti...
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today issued a statement confirming that it does not hold cash deposits or securities at Silicon Valley Bank. About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are...
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Heal...
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 4:40 p.m. ET, and host investor meetings. Investors interested in arranging a virtual meeting with the Compa...
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Car...
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at Cowen’s 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:50 p.m. ET, and host investor meetings. The conference is being held at the Boston Marriott Copley Place in Boston, Mass. I...
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurod...
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the proposed mechanisms of action of cannabidiol in FXS, Zygel™ showed a significant reduction in behavior...
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Pha...
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of resources on the completion of the RECONNECT trial DEVON, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies fo...
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2...
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, presented positive lo...
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Me...
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Ariz. A copy of the poster will be made available on the Zynerba corporate website following the presentation...
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CON...
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zygel in patients with a completely methylated FMR1 gene expected in second half 2023 DEVON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.